These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24086458)

  • 1. Characterization of naturally-occurring humoral immunity to AAV in sheep.
    Tellez J; Van Vliet K; Tseng YS; Finn JD; Tschernia N; Almeida-Porada G; Arruda VR; Agbandje-McKenna M; Porada CD
    PLoS One; 2013; 8(9):e75142. PubMed ID: 24086458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
    Boutin S; Monteilhet V; Veron P; Leborgne C; Benveniste O; Montus MF; Masurier C
    Hum Gene Ther; 2010 Jun; 21(6):704-12. PubMed ID: 20095819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structurally Mapping Antigenic Epitopes of Adeno-associated Virus 9: Development of Antibody Escape Variants.
    Emmanuel SN; Smith JK; Hsi J; Tseng YS; Kaplan M; Mietzsch M; Chipman P; Asokan A; McKenna R; Agbandje-McKenna M
    J Virol; 2022 Feb; 96(3):e0125121. PubMed ID: 34757842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adeno-associated virus serotype 1 (AAV1)- and AAV5-antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity.
    Tseng YS; Gurda BL; Chipman P; McKenna R; Afione S; Chiorini JA; Muzyczka N; Olson NH; Baker TS; Kleinschmidt J; Agbandje-McKenna M
    J Virol; 2015 Feb; 89(3):1794-808. PubMed ID: 25410874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.
    Scallan CD; Jiang H; Liu T; Patarroyo-White S; Sommer JM; Zhou S; Couto LB; Pierce GF
    Blood; 2006 Mar; 107(5):1810-7. PubMed ID: 16249376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.
    Moskalenko M; Chen L; van Roey M; Donahue BA; Snyder RO; McArthur JG; Patel SD
    J Virol; 2000 Feb; 74(4):1761-6. PubMed ID: 10644347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes.
    Sonntag F; Köther K; Schmidt K; Weghofer M; Raupp C; Nieto K; Kuck A; Gerlach B; Böttcher B; Müller OJ; Lux K; Hörer M; Kleinschmidt JA
    J Virol; 2011 Dec; 85(23):12686-97. PubMed ID: 21917944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models.
    Rapti K; Louis-Jeune V; Kohlbrenner E; Ishikawa K; Ladage D; Zolotukhin S; Hajjar RJ; Weber T
    Mol Ther; 2012 Jan; 20(1):73-83. PubMed ID: 21915102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming preexisting humoral immunity to AAV using capsid decoys.
    Mingozzi F; Anguela XM; Pavani G; Chen Y; Davidson RJ; Hui DJ; Yazicioglu M; Elkouby L; Hinderer CJ; Faella A; Howard C; Tai A; Podsakoff GM; Zhou S; Basner-Tschakarjan E; Wright JF; High KA
    Sci Transl Med; 2013 Jul; 5(194):194ra92. PubMed ID: 23863832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of binding and neutralizing antibodies against 18 adeno-associated virus types in patients with neuromuscular disorders.
    Wang X; Klann PJ; Wiedtke E; Sano Y; Fischer N; Schiller L; Elfert A; Güttsches AK; Weyen U; Grimm D; Vorgerd M; Bayer W
    Front Immunol; 2024; 15():1450858. PubMed ID: 39399494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capsid antibodies to different adeno-associated virus serotypes bind common regions.
    Gurda BL; DiMattia MA; Miller EB; Bennett A; McKenna R; Weichert WS; Nelson CD; Chen WJ; Muzyczka N; Olson NH; Sinkovits RS; Chiorini JA; Zolotutkhin S; Kozyreva OG; Samulski RJ; Baker TS; Parrish CR; Agbandje-McKenna M
    J Virol; 2013 Aug; 87(16):9111-24. PubMed ID: 23760240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.
    Li C; Diprimio N; Bowles DE; Hirsch ML; Monahan PE; Asokan A; Rabinowitz J; Agbandje-McKenna M; Samulski RJ
    J Virol; 2012 Aug; 86(15):7752-9. PubMed ID: 22593151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A.
    Klamroth R; Hayes G; Andreeva T; Gregg K; Suzuki T; Mitha IH; Hardesty B; Shima M; Pollock T; Slev P; Oldenburg J; Ozelo MC; Stieltjes N; Castet SM; Mahlangu J; Peyvandi F; Kazmi R; Schved JF; Leavitt AD; Callaghan M; Pan-Petesch B; Quon DV; Andrews J; Trinh A; Li M; Wong WY
    Hum Gene Ther; 2022 Apr; 33(7-8):432-441. PubMed ID: 35156839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Essential role of pre-existing humoral immunity in TLR9-mediated type I IFN response to recombinant AAV vectors in human whole blood.
    Alakhras NS; Moreland CA; Wong LC; Raut P; Kamalakaran S; Wen Y; Siegel RW; Malherbe LP
    Front Immunol; 2024; 15():1354055. PubMed ID: 39007143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia.
    Pabinger I; Ayash-Rashkovsky M; Escobar M; Konkle BA; Mingot-Castellano ME; Mullins ES; Negrier C; Pan L; Rajavel K; Yan B; Chapin J
    Gene Ther; 2024 May; 31(5-6):273-284. PubMed ID: 38355967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.
    Harrington EA; Sloan JL; Manoli I; Chandler RJ; Schneider M; McGuire PJ; Calcedo R; Wilson JM; Venditti CP
    Hum Gene Ther; 2016 May; 27(5):345-53. PubMed ID: 26790480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and rh10 in Healthy Donors.
    Xicluna R; Avenel A; Vandamme C; Devaux M; Jaulin N; Couzinié C; Le Duff J; Charrier A; Guilbaud M; Adjali O; Gernoux G
    Hum Gene Ther; 2024 May; 35(9-10):355-364. PubMed ID: 38581431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
    George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
    Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.